Sage Therapeutics Inc (NASDAQ:SAGE) Q1 2023 Earnings Call dated May. 02, 2023. Corporate Participants: Helen Rubinstein -- Director of Investor Relations Barry Greene -- Chief Executive
Sage Therapeutics Inc.
-(SAGE)
XNAS:SAGE
Sage Therapeutics Inc (SAGE) Q4 2022 Earnings Call Transcript
Sage Therapeutics Inc (NASDAQ: SAGE) Q4 2022 earnings call dated Feb. 16, 2023 Corporate Participants: Helen Rubinstein -- Director of Investor Relations Barry Greene -- Chief
Sage Therapeutics Inc (SAGE) Q3 2022 Earnings Call Transcript
Sage Therapeutics Inc (NASDAQ:SAGE) Q3 2022 Earnings Call dated Nov. 08, 2022. Corporate Participants: Helen Rubinstein -- Director of Investor Relations Barry Greene -- Chief Executive
Sage Therapeutics, Inc. (SAGE) Q2 2022 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q2 2022 earnings call dated Aug. 02, 2022 Corporate Participants: Helen Rubinstein -- Director of Investor Relations Barry Greene -- Chief
Sage Therapeutics Inc. (SAGE) Q1 2022 Earnings Call Transcript
Sage Therapeutics Inc. (NASDAQ: SAGE) Q1 2022 earnings call dated May. 03, 2022 Corporate Participants: Helen Rubinstein -- Investor Relations Barry Greene -- Chief Executive Officer
Sage Therapeutics, Inc. (SAGE) Q4 2021 Earnings Call Transcript
Sage Therapeutics, Inc. (NASDAQ: SAGE) Q4 2021 earnings call dated Feb. 24, 2022 Corporate Participants: Helen Rubinstein -- Investor Relations Officer Barry Greene -- Chief Executive
Sage Therapeutics Inc. (SAGE) Q4 2020 Earnings Call Transcript
Sage Therapeutics Inc. (NASDAQ: SAGE) Q4 2020 earnings call dated Feb. 24, 2021 Corporate Participants: Jeff Boyle -- Vice President, Head of Investor Relations
Sage Therapeutics Inc (SAGE) Q2 2020 Earnings Call Transcript
Sage Therapeutics Inc (NASDAQ: SAGE) Q2 2020 earnings call dated August 10, 2020 Corporate Participants: Jeff Boyle -- Senior Director of Investor Relations Jeff
Sage Therapeutics (SAGE) Q4 2019 Earnings Snapshot
-- Sage Therapeutics (NASDAQ: SAGE) reported fourth quarter 2019 loss of $3.25 per share vs. expected loss per share of $3.61. --